Guillain–Barre Syndrome Treatment Market – Global Industry Analysis and Forecast (2023-2029)


Guillain–Barre syndrome treatment Market was valued US$ 610.71 Mn in 2022 and is expected to reach US$ 870.86 Mn by 2029, at CAGR of 5.2% during forecast period of 2023 to 2029.

Guillain Barre Syndrome (GBS) is a rare neurological disorder in whThe report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.ich the body's immune system attacks part of the peripheral nervous system. It is one of several disorders involving weakness due to peripheral nerve damage caused by the person's immune system. Initial symptoms include unexplained sensations such as tingling in the feet or hands, or pain, followed by weakness on both sides of the body.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.Guillain-Barre Syndrome Treatment MarketTo know about the Research Methodology :- Request Free Sample Report

Global Guillain–Barre syndrome treatment Market Drivers and Restrains

Factors such as approvals from organizations such as the Food and Drug Administration (FDA), drug discoveries and novel therapeutics have contributed significant growth of the global Guillain-Barre Syndrome Treatment Market. Lack of awareness for the disease, absence of effective treatment are the major factors hinder the global Guillain Barre Syndrome treatment market, specifically in the underdeveloped regions. Physicians are introducing additional treatments that are cost effective and provide the best relief for all patients are fueling global Gillian Bare Syndrome treatment market in the forecast period.

Global Guillain–Barre syndrome treatment Market key segmentation

Global Guillain Barre Syndrome treatment Market is segmented By Therapeutics, type and distribution channel. By Therapeutics Global Guillain Barre Syndrome treatment Market is segmented in to Intravenous Immunoglobulin, Plasma Exchange and Others (Analgesics, Anticonvulsants, LMWH, etc.). Intravenous immunoglobulin IVIG is a treatment made from donated blood that contains healthy antibodies.

These are given to help stop the harmful antibodies damaging your nerves. Intravenous immunoglobin therapy is expected to have largest share of global market as intravenous immunoglobin therapy is more convenient and easily available. By Type the global market is divided into acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Miller Fisher syndrome treatment (MFS), acute motor axonal neuropathy (AMAN), and acute motor-sensory axonal neuropathy (AMSAN) .Among these Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), is expected to have xx% market share as it is the most common form in the U.S.

Global Guillain–Barre syndrome treatment Market Regional Analysis

Global Guillain Barre Syndrome treatment Market by region is segmented into Asia Pacific, North America, Europe, Latin America and Middle East Africa. The North American held the largest share global Guillain–Barré syndrome treatment Market thanks to well-developed healthcare sector and huge patient population. Furthermore, factors like the changing lifestyle and rise in investments in healthcare expenditure are boosting the growth of the regional market. Europe shares second highest share of global Guillain–Barré syndrome treatment.

Europe region is further categorized in to Europe – Western and Eastern Europe, Among them Western Europe is leading the Guillain Barre syndrome market in the region, while Eastern Europe is the fastest growing market in the region. The Asia Pacific region is emerged as fastest growing region for global Guillain–Barré syndrome market. Factors such as the technological advancements in the medical technologies and the fast-growing healthcare sector are propelling the growth of the market.

The objective of the report is to present comprehensive analysis of Global Guillain Barré syndrome treatment Market including all the stakeholders of the industry.The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Guillain–Barré syndrome treatment Market dynamics, structure by analyzing the market segments, and project the Global Guillain–Barré syndrome treatment Market size. Clear representation of competitive analysis of key players by Guillain–Barré syndrome treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Guillain–Barré syndrome treatment Market make the report investor’s guide.

Global Guillain–Barre syndrome treatment Market Scope :  Inquire before buying






Global Guillain–Barre syndrome treatment Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 610.71 Mn.




Forecast Period 2023 to 2029 CAGR:
5.2%
Market Size in 2029:
US $ 870.86 Mn




 Segments Covered:
by Product
Acute inflammatory demyelinating  polyradiculoneuropathy
Miller Fisher syndrome treatment
Acute motor axonal neuropathy
Acute motor-sensory axonal neuropathy




by Therapeutics
Intravenous Immunoglobulin
Plasma Exchange
Others (Analgesics, Anticonvulsants, LMWH, etc.)




by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others (Home Care, Clinics, etc.)






Global Guillain–Barre syndrome treatment Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Global Guillain–Barre syndrome treatment Market Key players

1. Akari Therapeutics Plc
2. Annexon Inc.
3. CuraVac Inc.
4. Hansa Medical AB
5. Regenesance BV
6. Vitality Biopharma Inc.
7. Grifols S.A.,
8. CSL Behring LLC,
9. Shire plc,
10.Octapharma AG,
11.Nihon Pharmaceutical Co., Ltd.,
12.Akari Therapeutics, PLC,
13.China Biologic Products Holdings,
14.Biotest AG,
15.Kedrion s.p.A
16.Natus Medical Inc.
17.Baxter

Frequently Asked Questions:

1. Which region has the largest share in Global Guillain–Barre syndrome treatment Market?
Ans: North America region holds the highest share in 2022.

2. What is the growth rate of Global Guillain–Barre syndrome treatment Market?
Ans: The Global Guillain–Barre syndrome treatment Market is growing at a CAGR of 5.2% during forecasting period 2023-2029.

3. What is scope of the Global Guillain–Barre syndrome treatment market report?
Ans: Global Guillain–Barre syndrome treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Guillain–Barre syndrome treatment market?
Ans: The important key players in the Global Guillain–Barre syndrome treatment Market are – Akari Therapeutics Plc, Annexon Inc., CuraVac Inc., Hansa Medical AB, Regenesance BV, Vitality Biopharma Inc., Grifols S.A.,, CSL Behring LLC,, Shire plc,, Octapharma AG,, Nihon Pharmaceutical Co., Ltd.,, Akari Therapeutics, PLC,, China Biologic Products Holdings,, Biotest AG,, Kedrion s.p.A, Natus Medical Inc., and Baxter

5. What is the study period of this market?
Ans: The Global Guillain–Barre syndrome treatment Market is studied from 2022 to 2029. 




Global Gillian Bare syndrome treatment Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Guillain Barre Syndrome Treatment Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Guillain Barre Syndrome Treatment Market Analysis and Forecast
6.1. Global Guillain Barre Syndrome Treatment Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Guillain Barre Syndrome Treatment Market Analysis and Forecast, by Therapeutics
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Guillain Barre Syndrome Treatment Market Value Share Analysis, by Therapeutics
7.4. Global Guillain Barre Syndrome Treatment Market Size (US$ Bn) Forecast, by Therapeutics
7.5. Global Guillain Barre Syndrome Treatment Market Analysis, by Therapeutics
7.6. Global Guillain Barre Syndrome Treatment Market Attractiveness Analysis, by Therapeutics

8. Global Guillain Barre Syndrome Treatment Market Analysis and Forecast, by Type
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Guillain Barre Syndrome Treatment Market Value Share Analysis, by Type
8.4. Global Guillain Barre Syndrome Treatment Market Size (US$ Bn) Forecast, by Type
8.5. Global Guillain Barre Syndrome Treatment Market Analysis, by Type
8.6. Global Guillain Barre Syndrome Treatment Market Attractiveness Analysis, by Type

9. Global Guillain Barre Syndrome Treatment Market Analysis and Forecast, by Distribution channel
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Guillain Barre Syndrome Treatment Market Value Share Analysis, by Distribution channel
9.4. Global Guillain Barre Syndrome Treatment Market Size (US$ Bn) Forecast, by Distribution channel
9.5. Global Guillain Barre Syndrome Treatment Market Analysis, by Distribution channel
9.6. Global Guillain Barre Syndrome Treatment Market Attractiveness Analysis, by Distribution channel

10. Global Guillain Barre Syndrome Treatment Market Analysis, by Region
10.1. Global Guillain Barre Syndrome Treatment Market Value Share Analysis, by Region
10.2. Global Guillain Barre Syndrome Treatment Market Size (US$ Bn) Forecast, by Region
10.3. Global Guillain Barre Syndrome Treatment Market Attractiveness Analysis, by Region

11. North America Guillain Barre Syndrome Treatment Market Analysis
11.1. Key Findings
11.2. North America Guillain Barre Syndrome Treatment Market Overview
11.3. North America Guillain Barre Syndrome Treatment Market Value Share Analysis, by Therapeutics
11.4. North America Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
11.4.1. Intravenous Immunoglobulin
11.4.2. Plasma Exchange
11.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
11.5. North America Guillain Barre Syndrome Treatment Market Value Share Analysis, by Type
11.6. North America Guillain Barre Syndrome Treatment Market Forecast, by Type
11.6.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
11.6.2. Miller Fisher syndrome treatment (MFS)
11.6.3. Acute motor axonal neuropathy (AMAN)
11.6.4. acute motor-sensory axonal neuropathy (AMSAN)
11.7. North America Guillain Barre Syndrome Treatment Market Value Share Analysis, by Distribution channel
11.8. North America Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Others (Home Care, Clinics, etc.)
11.9. North America Guillain Barre Syndrome Treatment Market Value Share Analysis, by Country
11.10. North America Guillain Barre Syndrome Treatment Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Guillain Barre Syndrome Treatment Market Analysis, by Country
11.12. U.S. Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
11.12.1. Intravenous Immunoglobulin
11.12.2. Plasma Exchange
11.12.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
11.13. U.S. Guillain Barre Syndrome Treatment Market Forecast, by Type
11.13.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
11.13.2. Miller Fisher syndrome treatment (MFS)
11.13.3. Acute motor axonal neuropathy (AMAN)
11.13.4. acute motor-sensory axonal neuropathy (AMSAN)
11.14. U.S. Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
11.14.1. Hospital Pharmacies
11.14.2. Retail Pharmacies
11.14.3. Others (Home Care, Clinics, etc.)
11.15. Canada Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
11.15.1. Intravenous Immunoglobulin
11.15.2. Plasma Exchange
11.15.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
11.16. Steel Canada Guillain Barre Syndrome Treatment Market Forecast, by Type
11.16.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
11.16.2. Miller Fisher syndrome treatment (MFS)
11.16.3. Acute motor axonal neuropathy (AMAN)
11.16.4. acute motor-sensory axonal neuropathy (AMSAN)
11.17. Canada Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
11.17.1. Hospital Pharmacies
11.17.2. Retail Pharmacies
11.17.3. Others (Home Care, Clinics, etc.)
11.18. North America Guillain Barre Syndrome Treatment Market Attractiveness Analysis
11.18.1. By Therapeutics
11.18.2. By Type
11.18.3. By Distribution channel
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Guillain Barre Syndrome Treatment Market Analysis
12.1. Key Findings
12.2. Europe Guillain Barre Syndrome Treatment Market Overview
12.3. Europe Guillain Barre Syndrome Treatment Market Value Share Analysis, by Therapeutics
12.4. Europe Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
12.4.1. Intravenous Immunoglobulin
12.4.2. Plasma Exchange
12.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
12.5. Europe Guillain Barre Syndrome Treatment Market Value Share Analysis, by Type
12.6. Europe Guillain Barre Syndrome Treatment Market Forecast, by Type
12.6.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
12.6.2. Miller Fisher syndrome treatment (MFS)
12.6.3. Acute motor axonal neuropathy (AMAN)
12.6.4. acute motor-sensory axonal neuropathy (AMSAN)
12.7. Europe Guillain Barre Syndrome Treatment Market Value Share Analysis, by Distribution channel
12.8. Europe Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Others (Home Care, Clinics, etc.)
12.9. Europe Guillain Barre Syndrome Treatment Market Value Share Analysis, by Country
12.10. Europe Guillain Barre Syndrome Treatment Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Guillain Barre Syndrome Treatment Market Analysis, by Country
12.12. Germany Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
12.12.1. Intravenous Immunoglobulin
12.12.2. Plasma Exchange
12.12.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
12.13. Germany Guillain Barre Syndrome Treatment Market Forecast, by Type
12.13.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
12.13.2. Miller Fisher syndrome treatment (MFS)
12.13.3. Acute motor axonal neuropathy (AMAN)
12.13.4. acute motor-sensory axonal neuropathy (AMSAN)
12.14. Germany Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
12.14.1. Hospital Pharmacies
12.14.2. Retail Pharmacies
12.14.3. Others (Home Care, Clinics, etc.)
12.15. U.K. Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
12.15.1. Intravenous Immunoglobulin
12.15.2. Plasma Exchange
12.15.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
12.16. U.K. Guillain Barre Syndrome Treatment Market Forecast, by Type
12.16.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
12.16.2. Miller Fisher syndrome treatment (MFS)
12.16.3. Acute motor axonal neuropathy (AMAN)
12.16.4. acute motor-sensory axonal neuropathy (AMSAN)
12.17. U.K. Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
12.17.1. Hospital Pharmacies
12.17.2. Retail Pharmacies
12.17.3. Others (Home Care, Clinics, etc.)
12.18. France Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
12.18.1. Intravenous Immunoglobulin
12.18.2. Plasma Exchange
12.18.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
12.19. France Guillain Barre Syndrome Treatment Market Forecast, by Type
12.19.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
12.19.2. Miller Fisher syndrome treatment (MFS)
12.19.3. Acute motor axonal neuropathy (AMAN)
12.19.4. acute motor-sensory axonal neuropathy (AMSAN)
12.20. France Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
12.20.1. Hospital Pharmacies
12.20.2. Retail Pharmacies
12.20.3. Others (Home Care, Clinics, etc.)
12.21. Italy Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
12.21.1. Intravenous Immunoglobulin
12.21.2. Plasma Exchange
12.21.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
12.22. Italy Guillain Barre Syndrome Treatment Market Forecast, by Type
12.22.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
12.22.2. Miller Fisher syndrome treatment (MFS)
12.22.3. Acute motor axonal neuropathy (AMAN)
12.22.4. acute motor-sensory axonal neuropathy (AMSAN)
12.23. Italy Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
12.23.1. Hospital Pharmacies
12.23.2. Retail Pharmacies
12.23.3. Others (Home Care, Clinics, etc.)
12.24. Spain Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
12.24.1. Intravenous Immunoglobulin
12.24.2. Plasma Exchange
12.24.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
12.25. Spain Guillain Barre Syndrome Treatment Market Forecast, by Type
12.25.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
12.25.2. Miller Fisher syndrome treatment (MFS)
12.25.3. Acute motor axonal neuropathy (AMAN)
12.25.4. acute motor-sensory axonal neuropathy (AMSAN)
12.26. Spain Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
12.26.1. Hospital Pharmacies
12.26.2. Retail Pharmacies
12.26.3. Others (Home Care, Clinics, etc.)
12.27. Rest of Europe Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
12.27.1. Intravenous Immunoglobulin
12.27.2. Plasma Exchange
12.27.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
12.28. Rest of Europe Guillain Barre Syndrome Treatment Market Forecast, by Type
12.28.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
12.28.2. Miller Fisher syndrome treatment (MFS)
12.28.3. Acute motor axonal neuropathy (AMAN)
12.28.4. acute motor-sensory axonal neuropathy (AMSAN)
12.29. Rest Of Europe Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
12.29.1. Hospital Pharmacies
12.29.2. Retail Pharmacies
12.29.3. Others (Home Care, Clinics, etc.)
12.30. Europe Guillain Barre Syndrome Treatment Market Attractiveness Analysis
12.30.1. By Therapeutics
12.30.2. By Type
12.30.3. By Distribution channel
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Guillain Barre Syndrome Treatment Market Analysis
13.1. Key Findings
13.2. Asia Pacific Guillain Barre Syndrome Treatment Market Overview
13.3. Asia Pacific Guillain Barre Syndrome Treatment Market Value Share Analysis, by Therapeutics
13.4. Asia Pacific Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
13.4.1. Intravenous Immunoglobulin
13.4.2. Plasma Exchange
13.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
13.5. Asia Pacific Guillain Barre Syndrome Treatment Market Value Share Analysis, by Type
13.6. Asia Pacific Guillain Barre Syndrome Treatment Market Forecast, by Type
13.6.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
13.6.2. Miller Fisher syndrome treatment (MFS)
13.6.3. Acute motor axonal neuropathy (AMAN)
13.6.4. acute motor-sensory axonal neuropathy (AMSAN)
13.7. Asia Pacific Guillain Barre Syndrome Treatment Market Value Share Analysis, by Distribution channel
13.8. Asia Pacific Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Others (Home Care, Clinics, etc.)
13.9. Asia Pacific Guillain Barre Syndrome Treatment Market Value Share Analysis, by Country
13.10. Asia Pacific Guillain Barre Syndrome Treatment Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Guillain Barre Syndrome Treatment Market Analysis, by Country
13.12. China Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
13.12.1. Intravenous Immunoglobulin
13.12.2. Plasma Exchange
13.12.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
13.13. China Guillain Barre Syndrome Treatment Market Forecast, by Type
13.13.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
13.13.2. Miller Fisher syndrome treatment (MFS)
13.13.3. Acute motor axonal neuropathy (AMAN)
13.13.4. acute motor-sensory axonal neuropathy (AMSAN)
13.14. China Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
13.14.1. Hospital Pharmacies
13.14.2. Retail Pharmacies
13.14.3. Others (Home Care, Clinics, etc.)
13.15. India Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
13.15.1. Intravenous Immunoglobulin
13.15.2. Plasma Exchange
13.15.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
13.16. India Guillain Barre Syndrome Treatment Market Forecast, by Type
13.16.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
13.16.2. Miller Fisher syndrome treatment (MFS)
13.16.3. Acute motor axonal neuropathy (AMAN)
13.16.4. acute motor-sensory axonal neuropathy (AMSAN)
13.17. India Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
13.17.1. Hospital Pharmacies
13.17.2. Retail Pharmacies
13.17.3. Others (Home Care, Clinics, etc.)
13.18. Japan Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
13.18.1. Intravenous Immunoglobulin
13.18.2. Plasma Exchange
13.18.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
13.19. Japan Guillain Barre Syndrome Treatment Market Forecast, by Type
13.19.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
13.19.2. Miller Fisher syndrome treatment (MFS)
13.19.3. Acute motor axonal neuropathy (AMAN)
13.19.4. acute motor-sensory axonal neuropathy (AMSAN)
13.20. Japan Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
13.20.1. Hospital Pharmacies
13.20.2. Retail Pharmacies
13.20.3. Others (Home Care, Clinics, etc.)
13.21. ASEAN Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
13.21.1. Intravenous Immunoglobulin
13.21.2. Plasma Exchange
13.21.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
13.22. ASEAN Guillain Barre Syndrome Treatment Market Forecast, by Type
13.22.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
13.22.2. Miller Fisher syndrome treatment (MFS)
13.22.3. Acute motor axonal neuropathy (AMAN)
13.22.4. acute motor-sensory axonal neuropathy (AMSAN)
13.23. ASEAN Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
13.23.1. Hospital Pharmacies
13.23.2. Retail Pharmacies
13.23.3. Others (Home Care, Clinics, etc.)
13.24. Rest of Asia Pacific Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
13.24.1. Intravenous Immunoglobulin
13.24.2. Plasma Exchange
13.24.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
13.25. Rest of Asia Pacific Guillain Barre Syndrome Treatment Market Forecast, by Type
13.25.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
13.25.2. Miller Fisher syndrome treatment (MFS)
13.25.3. Acute motor axonal neuropathy (AMAN)
13.25.4. acute motor-sensory axonal neuropathy (AMSAN)
13.26. Rest of Asia Pacific Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
13.26.1. Hospital Pharmacies
13.26.2. Retail Pharmacies
13.26.3. Others (Home Care, Clinics, etc.)
13.27. Asia Pacific Guillain Barre Syndrome Treatment Market Attractiveness Analysis
13.27.1. By Therapeutics
13.27.2. By Type
13.27.3. By Distribution channel
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Guillain Barre Syndrome Treatment Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Guillain Barre Syndrome Treatment Market Overview
14.3. Middle East & Africa Guillain Barre Syndrome Treatment Market Value Share Analysis, by Therapeutics
14.4. Middle East & Africa Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
14.4.1. Intravenous Immunoglobulin
14.4.2. Plasma Exchange
14.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
14.5. Middle East & Africa Guillain Barre Syndrome Treatment Market Value Share Analysis, by Type
14.6. Middle East & Africa Guillain Barre Syndrome Treatment Market Forecast, by Type
14.6.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
14.6.2. Miller Fisher syndrome treatment (MFS)
14.6.3. Acute motor axonal neuropathy (AMAN)
14.6.4. acute motor-sensory axonal neuropathy (AMSAN)
14.7. Middle East & Africa Guillain Barre Syndrome Treatment Market Value Share Analysis, by Distribution channel
14.8. Middle East & Africa Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Others (Home Care, Clinics, etc.)
14.9. Middle East & Africa Guillain Barre Syndrome Treatment Market Value Share Analysis, by Country
14.10. Middle East & Africa Guillain Barre Syndrome Treatment Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Guillain Barre Syndrome Treatment Market Analysis, by Country
14.12. GCC Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
14.12.1. Intravenous Immunoglobulin
14.12.2. Plasma Exchange
14.12.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
14.13. GCC Guillain Barre Syndrome Treatment Market Forecast, by Type
14.13.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
14.13.2. Miller Fisher syndrome treatment (MFS)
14.13.3. Acute motor axonal neuropathy (AMAN)
14.13.4. acute motor-sensory axonal neuropathy (AMSAN)
14.14. GCC Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
14.14.1. Hospital Pharmacies
14.14.2. Retail Pharmacies
14.14.3. Others (Home Care, Clinics, etc.)
14.15. South Africa Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
14.15.1. Intravenous Immunoglobulin
14.15.2. Plasma Exchange
14.15.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
14.16. South Africa Guillain Barre Syndrome Treatment Market Forecast, by Type
14.16.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
14.16.2. Miller Fisher syndrome treatment (MFS)
14.16.3. Acute motor axonal neuropathy (AMAN)
14.16.4. acute motor-sensory axonal neuropathy (AMSAN)
14.17. South Africa Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
14.17.1. Hospital Pharmacies
14.17.2. Retail Pharmacies
14.17.3. Others (Home Care, Clinics, etc.)
14.18. Rest of Middle East & Africa Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
14.18.1. Intravenous Immunoglobulin
14.18.2. Plasma Exchange
14.18.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
14.19. Rest of Middle East & Africa Guillain Barre Syndrome Treatment Market Forecast, by Type
14.19.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
14.19.2. Miller Fisher syndrome treatment (MFS)
14.19.3. Acute motor axonal neuropathy (AMAN)
14.19.4. acute motor-sensory axonal neuropathy (AMSAN)
14.20. Rest of Middle East & Africa Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
14.20.1. Hospital Pharmacies
14.20.2. Retail Pharmacies
14.20.3. Others (Home Care, Clinics, etc.)
14.21. Middle East & Africa Guillain Barre Syndrome Treatment Market Attractiveness Analysis
14.21.1. By Therapeutics
14.21.2. By Type
14.21.3. By Distribution channel
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Guillain Barre Syndrome Treatment Market Analysis
15.1. Key Findings
15.2. South America Guillain Barre Syndrome Treatment Market Overview
15.3. South America Guillain Barre Syndrome Treatment Market Value Share Analysis, by Therapeutics
15.4. South America Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
15.4.1. Intravenous Immunoglobulin
15.4.2. Plasma Exchange
15.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
15.5. South America Guillain Barre Syndrome Treatment Market Value Share Analysis, by Type
15.6. South America Guillain Barre Syndrome Treatment Market Forecast, by Type
15.6.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
15.6.2. Miller Fisher syndrome treatment (MFS)
15.6.3. Acute motor axonal neuropathy (AMAN)
15.6.4. acute motor-sensory axonal neuropathy (AMSAN)
15.7. South America Guillain Barre Syndrome Treatment Market Value Share Analysis, by Distribution channel
15.8. South America Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Others (Home Care, Clinics, etc.)

15.9. South America Guillain Barre Syndrome Treatment Market Value Share Analysis, by Country
15.10. South America Guillain Barre Syndrome Treatment Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Guillain Barre Syndrome Treatment Market Analysis, by Country
15.12. Brazil Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
15.12.1. Intravenous Immunoglobulin
15.12.2. Plasma Exchange
15.12.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
15.13. Brazil Guillain Barre Syndrome Treatment Market Forecast, by Type
15.13.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
15.13.2. Miller Fisher syndrome treatment (MFS)
15.13.3. Acute motor axonal neuropathy (AMAN)
15.13.4. acute motor-sensory axonal neuropathy (AMSAN)
15.14. Brazil Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
15.14.1. Hospital Pharmacies
15.14.2. Retail Pharmacies
15.14.3. Others (Home Care, Clinics, etc.)
15.15. Mexico Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
15.15.1. Intravenous Immunoglobulin
15.15.2. Plasma Exchange
15.15.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
15.16. Mexico Guillain Barre Syndrome Treatment Market Forecast, by Type
15.16.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
15.16.2. Miller Fisher syndrome treatment (MFS)
15.16.3. Acute motor axonal neuropathy (AMAN)
15.16.4. acute motor-sensory axonal neuropathy (AMSAN)
15.17. Mexico Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
15.17.1. Hospital Pharmacies
15.17.2. Retail Pharmacies
15.17.3. Others (Home Care, Clinics, etc.)
15.18. Rest of South America Guillain Barre Syndrome Treatment Market Forecast, by Therapeutics
15.18.1. Intravenous Immunoglobulin
15.18.2. Plasma Exchange
15.18.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
15.19. Rest of South America Guillain Barre Syndrome Treatment Market Forecast, by Type
15.19.1. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
15.19.2. Miller Fisher syndrome treatment (MFS)
15.19.3. Acute motor axonal neuropathy (AMAN)
15.19.4. acute motor-sensory axonal neuropathy (AMSAN)
15.20. Rest of South America Guillain Barre Syndrome Treatment Market Forecast, by Distribution channel
15.20.1. Hospital Pharmacies
15.20.2. Retail Pharmacies
15.20.3. Others (Home Care, Clinics, etc.)
15.21. South America Guillain Barre Syndrome Treatment Market Attractiveness Analysis
15.21.1. By Therapeutics
15.21.2. By Type
15.21.3. By distribution channel
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Akari Therapeutics Plc
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Annexon Inc.
16.3.3. CuraVac Inc.
16.3.4. Hansa Medical AB
16.3.5. Regenesance BV
16.3.6. Vitality Biopharma Inc.
16.3.7. Grifols S.A.,
16.3.8. CSL Behring LLC,
16.3.9. Shire plc,
16.3.10. Octapharma AG,
16.3.11. Nihon Pharmaceutical Co., Ltd.,
16.3.12. China Biologic Products Holdings,
16.3.13. Biotest AG,
16.3.14. Kedrion s.p.A
16.3.15. Natus Medical Inc.
16.3.16. Baxter

17. Primary Key Insights
  • INQUIRE BEFORE BUYING